Three Deeply Discounted Dividend Equities Worth Acquiring Now
Yahoo Finance ·
As the S&P 500 hovers near record levels with a lofty valuation of 23.5 times earnings and a 1.1% yield, compelling bargains still exist among prominent dividend payers. Pfizer (PFE), T. Rowe Price (TROW), and Verizon Communications (VZ) stand out because market participants have overly penalized them for temporary setbacks. For Pfizer, top and bottom lines retreated following the pandemic boom, compounded by upcoming patent cliffs for major legacy drugs like Eliquis. Nevertheless, the shares change hands at a mere 9.6 times forward earnings, well below pharmaceutical peers boasting robust pipelines. Should its ongoing drug development efforts bear fruit—including obesity candidates gained through the Metsera acquisition—Pfizer shares could achieve a significant multiple expansion. Meanwhile, income-focused investors can secure an attractive 5.6% dividend yield backed by a manageable payout ratio sitting just under 60%.
AI 시장 분석
As the S&P 500 enters an overvalued phase with a price-to-earnings ratio of 23.5x, three undervalued blue-chip dividend stocks are gaining attention: Pfizer, T. Rowe Price, and Verizon. Pfizer's valuation has dropped to 9.6x due to declining vaccine sales and patent expiration concerns, though analysts consider this an overreaction. Investors should weigh its high 5.6% dividend yield and the potential for valuation re-rating through pipeline performance.
상승 영향
- Biotechnology — Pfizer offers an inexpensive valuation with a forward P/E of 9.6x and a high dividend yield of 5.6%, with a stock re-rating expected based on new drug pipeline achievements such as obesity treatments.
하락 영향
- Biotechnology — Continued revenue declines in COVID-19-related products and patent expirations for key non-COVID drugs like Eliquis are applying downward pressure on the stock price.
DYAX 전담 분석
Pfizer faces downward stock pressure from plunging COVID-19 product sales and patent expirations on major drugs like Eliquis, with its forward P/E sitting at around 9.6x, lower than competitors. However, clinical success in new drug pipelines, such as obesity treatments, will be the core driver for future earnings rebounds and stock re-rating.
In the bullish scenario, the stock could rebound through successful new drug development and maintained dividends (payout ratio below 60%), while the bearish scenario could highlight additional patent expiration hits and dividend cut risks. Investors must closely monitor upcoming pipeline clinical data and quarterly earnings trends.
AI가 생성한 분석으로 투자 자문이 아닙니다.
DYAX Investor Sentiment
Bullish (Long) 64% · Bearish (Short) 36%
399 participants
Related News
- SoFi Shares Surge 13 Percent Following Upbeat Financial Guidance
- US Stock Futures Mixed As Investors Await Fed Rate Decision And Tech Earnings
- OpenAI Plans to Purchase Google AI Chips to Boost Computing Power
- LS Mtron Targets Multi-Billion Dollar Windfall in Audi US Plant Supply Race
- SK Hynix CEO Kwak Noh-jung Halts Solidigm IPO While Maintaining Growth Investments
- What JPMorgan Chase Losing $1.4B in Advisory Assets Means for JPM
